Gain Therapeutics, Inc.
GANX
$3.32
$0.268.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 3.28% | 22.46% | |||
| Gross Profit | -3.28% | -22.46% | |||
| SG&A Expenses | -16.57% | 10.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.96% | 16.47% | |||
| Operating Income | 5.96% | -16.47% | |||
| Income Before Tax | 16.46% | -27.96% | |||
| Income Tax Expenses | 289.02% | 40.50% | |||
| Earnings from Continuing Operations | 9.03% | -28.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.03% | -28.23% | |||
| EBIT | 5.96% | -16.47% | |||
| EBITDA | 6.00% | -16.52% | |||
| EPS Basic | 21.15% | -21.28% | |||
| Normalized Basic EPS | 27.57% | -21.04% | |||
| EPS Diluted | 21.15% | -21.28% | |||
| Normalized Diluted EPS | 27.57% | -21.04% | |||
| Average Basic Shares Outstanding | 15.35% | 5.77% | |||
| Average Diluted Shares Outstanding | 15.35% | 5.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||